Delcath Systems Inc (DCTH)vsEdwards Lifesciences Corp (EW)
DCTH
Delcath Systems Inc
$13.01
-3.77%
HEALTHCARE · Cap: $446.71M
EW
Edwards Lifesciences Corp
$92.21
+0.96%
HEALTHCARE · Cap: $54.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 6870% more annual revenue ($6.30B vs $90.44M). EW leads profitability with a 17.4% profit margin vs 0.6%. DCTH appears more attractively valued with a PEG of 1.60. EW earns a higher WallStSmart Score of 56/100 (C).
DCTH
Hold35
out of 100
Grade: F
EW
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DCTH.
Margin of Safety
+68.5%
Fair Value
$251.46
Current Price
$92.21
$159.25 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 26.3% year-over-year
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
16.7% revenue growth
Areas to Watch
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of 0.5% — below average capital efficiency
0.6% margin — thin
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : DCTH
The strongest argument for DCTH centers on Debt/Equity, Revenue Growth. Revenue growth of 26.3% demonstrates continued momentum.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : DCTH
The primary concerns for DCTH are PEG Ratio, Market Cap, Return on Equity. A P/E of 1294.0x leaves little room for execution misses. Thin 0.6% margins leave little buffer for downturns.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.3x leaves little room for execution misses.
Key Dynamics to Monitor
EW carries more volatility with a beta of 0.85 — expect wider price swings.
DCTH is growing revenue faster at 26.3% — sustainability is the question.
DCTH generates stronger free cash flow (287,000), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
EW scores higher overall (56/100 vs 35/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Delcath Systems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?